Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

20.29 -0.88 (-4.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Company to host webcast on Thursday, June 12 at 6:00 pm ET 
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
Phase 2 study fully enrolled; data expected in 2H 2025 
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.